Some of those genes are already well-known as tumor-suppressor genes (e.g., APC, BRCA1, CDKN2A, PTCH1, PTEN, SMAD4, TP53), and oncogenes (e.g., FGFR1, MET, PIK3CA) (Table S6) and genes that tyrosine kinases can use as a therapeutic target (e.g., PIK3CA, AKT, FGFR1) and all mapped at aUPD regions we observed. This evidence concerns the gene SMAD4 and neoplasm.